cccc-20240930000166257912-312023Q1FALSEhttp://fasb.org/us-gaap/2024#CollaborativeArrangementMemberhttp://fasb.org/us-gaap/2024#CollaborativeArrangementMemberP2Dxbrli:sharesiso4217:USDiso4217:USDxbrli:sharescccc:targetcccc:performanceObligationxbrli:purecccc:protein00016625792024-01-012024-09-3000016625792024-10-2400016625792024-09-3000016625792023-12-3100016625792023-01-012023-09-3000016625792024-07-012024-09-3000016625792023-07-012023-09-300001662579us-gaap:CommonStockMember2023-12-310001662579us-gaap:AdditionalPaidInCapitalMember2023-12-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001662579us-gaap:RetainedEarningsMember2023-12-310001662579us-gaap:CommonStockMembercccc:StockPurchaseAgreementMember2024-01-012024-03-310001662579us-gaap:AdditionalPaidInCapitalMembercccc:StockPurchaseAgreementMember2024-01-012024-03-310001662579cccc:StockPurchaseAgreementMember2024-01-012024-03-310001662579us-gaap:CommonStockMembercccc:AtTheMarketMember2024-01-012024-03-310001662579us-gaap:AdditionalPaidInCapitalMembercccc:AtTheMarketMember2024-01-012024-03-310001662579cccc:AtTheMarketMember2024-01-012024-03-310001662579us-gaap:CommonStockMember2024-01-012024-03-310001662579us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100016625792024-01-012024-03-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001662579us-gaap:RetainedEarningsMember2024-01-012024-03-310001662579us-gaap:CommonStockMember2024-03-310001662579us-gaap:AdditionalPaidInCapitalMember2024-03-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001662579us-gaap:RetainedEarningsMember2024-03-3100016625792024-03-310001662579us-gaap:CommonStockMember2024-04-012024-06-300001662579us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000016625792024-04-012024-06-300001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001662579us-gaap:RetainedEarningsMember2024-04-012024-06-300001662579us-gaap:CommonStockMember2024-06-300001662579us-gaap:AdditionalPaidInCapitalMember2024-06-300001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001662579us-gaap:RetainedEarningsMember2024-06-3000016625792024-06-300001662579us-gaap:CommonStockMembercccc:AtTheMarketMember2024-07-012024-09-300001662579us-gaap:AdditionalPaidInCapitalMembercccc:AtTheMarketMember2024-07-012024-09-300001662579cccc:AtTheMarketMember2024-07-012024-09-300001662579us-gaap:CommonStockMember2024-07-012024-09-300001662579us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001662579us-gaap:RetainedEarningsMember2024-07-012024-09-300001662579us-gaap:CommonStockMember2024-09-300001662579us-gaap:AdditionalPaidInCapitalMember2024-09-300001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001662579us-gaap:RetainedEarningsMember2024-09-300001662579us-gaap:CommonStockMember2022-12-310001662579us-gaap:AdditionalPaidInCapitalMember2022-12-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001662579us-gaap:RetainedEarningsMember2022-12-3100016625792022-12-310001662579us-gaap:CommonStockMember2023-01-012023-03-310001662579us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100016625792023-01-012023-03-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001662579us-gaap:RetainedEarningsMember2023-01-012023-03-310001662579us-gaap:CommonStockMember2023-03-310001662579us-gaap:AdditionalPaidInCapitalMember2023-03-310001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001662579us-gaap:RetainedEarningsMember2023-03-3100016625792023-03-310001662579us-gaap:CommonStockMember2023-04-012023-06-300001662579us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000016625792023-04-012023-06-300001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001662579us-gaap:RetainedEarningsMember2023-04-012023-06-300001662579us-gaap:CommonStockMember2023-06-300001662579us-gaap:AdditionalPaidInCapitalMember2023-06-300001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001662579us-gaap:RetainedEarningsMember2023-06-3000016625792023-06-300001662579us-gaap:CommonStockMember2023-07-012023-09-300001662579us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001662579us-gaap:RetainedEarningsMember2023-07-012023-09-300001662579us-gaap:CommonStockMember2023-09-300001662579us-gaap:AdditionalPaidInCapitalMember2023-09-300001662579us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001662579us-gaap:RetainedEarningsMember2023-09-3000016625792023-09-300001662579cccc:AtTheMarketMember2024-01-012024-09-300001662579cccc:AtTheMarketMember2023-01-012023-09-300001662579cccc:StockPurchaseAgreementMember2024-01-012024-09-300001662579cccc:StockPurchaseAgreementMember2023-01-012023-09-300001662579us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300001662579us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300001662579us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300001662579us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001662579us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001662579us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001662579us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001662579us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001662579us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001662579us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001662579us-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001662579us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001662579us-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001662579us-gaap:CorporateDebtSecuritiesMember2024-09-300001662579us-gaap:USTreasurySecuritiesMember2024-09-300001662579us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001662579us-gaap:CorporateDebtSecuritiesMember2023-12-310001662579us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001662579us-gaap:USTreasurySecuritiesMember2023-12-310001662579cccc:LaboratoryEquipmentMember2024-09-300001662579cccc:LaboratoryEquipmentMember2023-12-310001662579us-gaap:LeaseholdsAndLeaseholdImprovementsMember2024-09-300001662579us-gaap:LeaseholdsAndLeaseholdImprovementsMember2023-12-310001662579us-gaap:FurnitureAndFixturesMember2024-09-300001662579us-gaap:FurnitureAndFixturesMember2023-12-310001662579us-gaap:OfficeEquipmentMember2024-09-300001662579us-gaap:OfficeEquipmentMember2023-12-310001662579us-gaap:ComputerEquipmentMember2024-09-300001662579us-gaap:ComputerEquipmentMember2023-12-310001662579cccc:MKDGAgreementMember2024-03-010001662579cccc:MKDGAgreementMember2024-03-012024-03-010001662579cccc:DiscoveryRegulatoryAndCommercialMilestonesMembercccc:MKDGAgreementMember2024-09-300001662579srt:MinimumMembercccc:MKDGAgreementMember2024-03-012024-03-010001662579cccc:MKDGAgreementMember2024-09-300001662579cccc:MKDGAgreementMember2024-09-300001662579cccc:MerckAgreementMember2023-12-112023-12-110001662579cccc:ResearchAndDevelopmentMilestonesMembercccc:MerckAgreementMember2023-12-110001662579cccc:MerckAgreementMember2023-12-110001662579srt:MinimumMembercccc:MerckAgreementMember2023-12-112023-12-110001662579cccc:MerckAgreementMember2024-09-300001662579cccc:BettaAgreementMember2023-05-292023-05-290001662579cccc:ResearchAndDevelopmentMilestonesMembercccc:BettaAgreementMember2023-05-290001662579cccc:DrugApplicationApprovalMembercccc:BettaAgreementMember2023-05-290001662579cccc:BettaAgreementMember2023-05-290001662579srt:MinimumMember2023-05-292023-05-290001662579cccc:BettaAgreementMember2024-09-300001662579cccc:BettaAgreementMember2024-09-302024-09-300001662579cccc:BettaAgreementMember2023-12-012023-12-310001662579cccc:BettaAgreementMember2023-07-012023-09-300001662579cccc:RestatedRocheAgreementMember2018-12-012018-12-310001662579cccc:RestatedRocheAgreementMember2020-11-300001662579cccc:RestatedRocheAgreementMember2023-12-310001662579cccc:LeadSeriesIdentificationAchievementMembercccc:RestatedRocheAgreementMember2020-11-012020-11-300001662579cccc:RestatedRocheAgreementMember2020-11-012020-11-300001662579cccc:ResearchDevelopmentAndCommercialMilestonePaymentsMembersrt:MaximumMembercccc:RestatedRocheAgreementMember2020-11-300001662579cccc:OneTimeSalesBasedPaymentsMembersrt:MaximumMembercccc:RestatedRocheAgreementMember2020-11-300001662579srt:MinimumMembercccc:RestatedRocheAgreementMember2020-11-012020-11-3000016625792018-12-310001662579cccc:RestatedRocheAgreementMember2018-12-310001662579cccc:ResearchAndDevelopmentTargetsMember2024-09-300001662579cccc:OptionRightsMember2024-09-300001662579srt:MaximumMembercccc:BiogenResearchAndLicenseAgreementMember2020-02-012020-02-290001662579cccc:BiogenResearchAndLicenseAgreementMember2020-02-012020-02-290001662579cccc:ResearchAndDevelopmentMilestonesMembersrt:MaximumMembercccc:BiogenResearchAndLicenseAgreementMember2020-02-012020-02-290001662579cccc:OneTimeSalesBasedPaymentsMembersrt:MaximumMembercccc:BiogenResearchAndLicenseAgreementMember2020-02-012020-02-290001662579cccc:ResearchAndDevelopmentServicesMembercccc:BiogenResearchAndLicenseAgreementMember2024-01-012024-09-300001662579cccc:BiogenResearchAndLicenseAgreementMember2024-04-012024-04-300001662579cccc:BiogenResearchAndLicenseAgreementMember2024-09-012024-09-300001662579cccc:CalicoLicenseAgreementMember2017-03-012017-03-310001662579cccc:CalicoLicenseAgreementMember2021-08-012021-08-310001662579cccc:CalicoLicenseAgreementMember2017-03-012020-06-300001662579cccc:PotentialResearchDevelopmentAndCommercialMilestonePaymentsMembersrt:MaximumMembercccc:CalicoLicenseAgreementMember2017-03-012017-03-310001662579cccc:OneTimeSalesBasedPaymentsMembersrt:MaximumMembercccc:CalicoLicenseAgreementMember2017-03-012017-03-310001662579cccc:MKDGAgreementMember2024-07-012024-09-300001662579cccc:MKDGAgreementMember2023-07-012023-09-300001662579cccc:MKDGAgreementMember2024-01-012024-09-300001662579cccc:MKDGAgreementMember2023-01-012023-09-300001662579cccc:MerckAgreementMember2024-07-012024-09-300001662579cccc:MerckAgreementMember2023-07-012023-09-300001662579cccc:MerckAgreementMember2024-01-012024-09-300001662579cccc:MerckAgreementMember2023-01-012023-09-300001662579cccc:BettaAgreementMember2024-07-012024-09-300001662579cccc:BettaAgreementMember2024-01-012024-09-300001662579cccc:BettaAgreementMember2023-01-012023-09-300001662579cccc:RocheAgreementMember2024-07-012024-09-300001662579cccc:RocheAgreementMember2023-07-012023-09-300001662579cccc:RocheAgreementMember2024-01-012024-09-300001662579cccc:RocheAgreementMember2023-01-012023-09-300001662579cccc:BiogenAgreementMember2024-07-012024-09-300001662579cccc:BiogenAgreementMember2023-07-012023-09-300001662579cccc:BiogenAgreementMember2024-01-012024-09-300001662579cccc:BiogenAgreementMember2023-01-012023-09-300001662579cccc:CalicoAgreementMember2024-07-012024-09-300001662579cccc:CalicoAgreementMember2023-07-012023-09-300001662579cccc:CalicoAgreementMember2024-01-012024-09-300001662579cccc:CalicoAgreementMember2023-01-012023-09-300001662579cccc:RocheAgreementMember2024-09-300001662579cccc:BiogenAgreementMember2024-09-300001662579cccc:MerckAgreementMember2023-12-310001662579cccc:BettaAgreementMember2023-12-310001662579cccc:RocheAgreementMember2023-12-310001662579cccc:BiogenAgreementMember2023-12-310001662579cccc:RestatedRocheAgreementAndBiogenLicenseAgreementMember2024-09-300001662579cccc:AtTheMarketMembersrt:MaximumMembercccc:EquityDistributionAgreementWithCowenAndCompanyLLCMember2021-11-300001662579cccc:AtTheMarketMembercccc:EquityDistributionAgreementWithCowenAndCompanyLLCMember2024-07-012024-09-300001662579cccc:AtTheMarketMembercccc:EquityDistributionAgreementWithCowenAndCompanyLLCMember2024-01-012024-09-300001662579cccc:AtTheMarketMembercccc:EquityDistributionAgreementWithCowenAndCompanyLLCMember2023-01-012023-09-300001662579cccc:AtTheMarketMembercccc:EquityDistributionAgreementWithCowenAndCompanyLLCMember2023-07-012023-09-300001662579cccc:AtTheMarketMembercccc:EquityDistributionAgreementWithCowenAndCompanyLLCMember2021-11-012024-06-300001662579cccc:AtTheMarketMembercccc:EquityDistributionAgreementWithCowenAndCompanyLLCMember2024-09-300001662579us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001662579us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001662579us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001662579us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001662579us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001662579us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001662579us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001662579us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001662579us-gaap:EmployeeStockOptionMember2024-09-300001662579us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001662579cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember2024-03-072024-03-070001662579cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember2024-07-012024-09-300001662579cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember2024-01-012024-09-300001662579us-gaap:PerformanceSharesMember2024-01-012024-09-300001662579us-gaap:PerformanceSharesMember2024-09-300001662579us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001662579us-gaap:RestrictedStockUnitsRSUMember2024-09-300001662579cccc:OptionsToPurchaseCommonStockMember2024-01-012024-09-300001662579cccc:OptionsToPurchaseCommonStockMember2023-01-012023-09-3000016625792024-01-012024-01-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________________________________________________
FORM 10-Q
________________________________________________
(Mark One)
| | | | | |
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2024
OR
| | | | | |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ___________________ to ___________________
Commission File Number: 001-39567
________________________________________________
C4 Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
________________________________________________
| | | | | |
Delaware | 47-5617627 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
490 Arsenal Way, Suite 120 Watertown, MA | 02472 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (617) 231-0700
________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, $0.0001 par value per share | | CCCC | | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | |
Large accelerated filer | o | | Accelerated filer | o | |
Non-accelerated filer | x | | Smaller reporting company | x | |
| | | Emerging growth company | o | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ o No x
As of October 24, 2024, the registrant had 70,588,959 shares of common stock, $0.0001 par value per share, outstanding.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, or Form 10-Q, including the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Form 10-Q may include, but are not limited to, statements about:
•the initiation, timing, progress, results, safety and efficacy, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials, the period during which the results of the trials will become available, and our research and development programs;
•our ability to obtain funding for our operations necessary to complete further development, manufacturing and commercialization of our product candidates;
•our ability to obtain and maintain regulatory approval for any of our current or future product candidates;
•the period of time over which we anticipate our existing cash and cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements;
•our ability to identify and develop product candidates for treatment of additional disease indications;
•the potential attributes and benefits of our product candidates;
•the rate and degree of market acceptance and clinical utility for any product candidates we may develop;
•the pricing and reimbursement of our product candidates, if approved, including the possibility for reduced pricing of our products, once approved, if they are later subject to mandatory price negotiation with the Centers for Medicare and Medicaid Services under the Inflation Reduction Act of 2022 or other applicable laws;
•the effects of competition with respect to any of our current or future product candidates, as well as innovations by current and future competitors in our industry;
•the implementation of our strategic plans for our business, any product candidates we may develop, and our TORPEDO® (Target ORiented ProtEin Degrader Optimizer) platform;
•the ability and willingness of our third-party strategic collaborators to continue research, development, and manufacturing activities relating to our product candidates, including our ability to advance programs under our existing collaboration agreements with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or Roche, Betta Pharmaceuticals, Co., Ltd., or Betta Pharma, Merck Sharp & Dohme, LLC, or Merck, and Merck KGaA, Darmstadt, Germany, or MKDG, or other new collaboration agreements;
•the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;
•estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;
•future agreements with third parties in connection with the manufacturing and commercialization of our product candidates, if approved;
•the size and growth potential of the markets for our product candidates and our ability to serve those markets;
•our financial performance;
•regulatory developments in the United States and foreign countries;
•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
•the success of competing therapies that are or may become available;
•our ability to attract and retain key scientific or management personnel;
•developments relating to our competitors and our industry; and
•other risks and uncertainties, including those discussed in Part II, Item 1A - Risk Factors in this Form 10-Q.
In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled “Risk Factors” and elsewhere in this Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a promise or a guarantee of future performance.
The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q.
SUMMARY OF RISK FACTORS
Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in Part II, Item 1A - Risk Factors in this Form 10-Q. These risks include, among others:
•We are a clinical-stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. To date, we have not generated any revenue from product sales. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years and may never achieve or maintain profitability. Our net loss was $70.7 million and $97.7 million for the nine months ended September 30, 2024 and 2023, respectively.
•We will need substantial additional funding to pursue our business objectives and continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts.
•Our approach to the discovery and development of product candidates based on our TORPEDO platform is unproven, which makes it difficult to predict the time, cost and likelihood of successfully developing any products.
•While we are a clinical-stage company and have commenced clinical trials of several product candidates, we have never completed a clinical trial of any of our product candidates. Our business could be harmed if we are unable to develop, obtain regulatory approval for and/or commercialize our product candidates, or if we experience significant delays in doing any of these things.
•We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials. In addition, the results of preclinical studies may not be predictive of the results of clinical trials and the results of any early-stage clinical trials we commence may not be predictive of the results of later-stage clinical trials.
•Our preclinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent, delay, or require additional research or analysis to proceed with development, regulatory approval, and commercialization of our current and future product candidates.
•We have ongoing collaborations with Roche, Betta Pharma, Merck, and MKDG. We may also seek to enter into additional collaborations in the future with third parties for the discovery, development and/or commercialization of certain of our product candidates. However, we may never realize the full potential benefits under these existing or potential collaboration arrangements.
•We face substantial competition, which may result in others discovering, developing or commercializing products for the same indication and/or patient population before or more successfully than we do.
•We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates in a timely manner, or at an acceptable cost or quality.
•If we are unable to obtain required marketing approvals for, commercialize, manufacture, obtain, and maintain patent protection for or gain market acceptance of our product candidates, or if we experience significant delays in doing so, our business will be materially harmed and our ability to generate revenue from product sales will be materially impaired.
•If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad or enforceable, our competitors could develop and commercialize technology, product candidates, and products similar or identical to ours, and our ability to successfully commercialize our technology, product candidates, and products may be impaired.
NOTE REGARDING COMPANY REFERENCES
Unless the context otherwise requires, the terms “C4 Therapeutics,” “the Company,” “we,” “us,” and “our” in this Form 10-Q refer to C4 Therapeutics, Inc. and its consolidated subsidiary.
NOTE REGARDING TRADEMARKS
We own or have rights to various trademarks, service marks and trade names that are used in connection with the operation of our business, including our company name, C4 Therapeutics, our logo, the name of our TORPEDO technology platform and the names of our BIDAC and MONODAC protein degrader product candidates. This Form 10-Q may also contain trademarks, service marks, and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names, or products in this prospectus is not intended to and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks, and trade names referred to in this prospectus may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks, and trade names.
Table of Contents
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
C4 Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
| | | | | | | | | | | |
| September 30, 2024 | | December 31, 2023 |
Assets | | | |
Current assets: | | | |
Cash and cash equivalents | $ | 59,649 | | | $ | 126,590 | |
Marketable securities, current | 195,992 | | | 127,091 | |
Accounts receivable | 10,341 | | | 11,799 | |
Prepaid expenses and other current assets | 7,246 | | | 5,709 | |
Total current assets | 273,228 | | | 271,189 | |
Marketable securities, non-current | 28,759 | | | 28,008 | |
Property and equipment, net | 6,206 | | | 7,132 | |
Right-of-use asset | 59,167 | | | 63,956 | |
Restricted cash | 3,443 | | | 3,443 | |
Other assets | 5,257 | | | 2,723 | |
Total assets | $ | 376,060 | | | $ | 376,451 | |
Liabilities and Stockholders’ Equity | | | |
Current liabilities: | | | |
Accounts payable | $ | 1,504 | | | $ | 1,446 | |
Accrued expenses and other current liabilities | 15,388 | | | 20,630 | |
Deferred revenue, current | 20,769 | | | 15,471 | |
Operating lease liability, current | 5,632 | | | 5,219 | |
Total current liabilities | 43,293 | | | 42,766 | |
Deferred revenue, net of current | 28,648 | | | 21,814 | |
Operating lease liability, net of current | 61,463 | | | 65,757 | |
Total liabilities | 133,404 | | | 130,337 | |
Commitments and contingencies (see Note 11) | | | |
Stockholders’ equity: | | | |
Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of September 30, 2024 and December 31, 2023, respectively | — | | | — | |
Common stock, par value of $0.0001 per share; 150,000,000 shares authorized, and 70,562,901 and 60,467,188 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 7 | | | 6 | |
Additional paid-in capital | 841,320 | | | 774,618 | |
Accumulated other comprehensive income (loss) | 455 | | | (127) | |
Accumulated deficit | (599,126) | | | (528,383) | |
Total stockholders’ equity | 242,656 | | | 246,114 | |
Total liabilities and stockholders’ equity | $ | 376,060 | | | $ | 376,451 | |
See accompanying notes to unaudited condensed consolidated financial statements.
C4 Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Revenue from collaboration agreements | $ | 15,362 | | | $ | 11,072 | | | $ | 30,407 | | | $ | 17,495 | |
Operating expenses: | | | | | | | |
Research and development | 31,838 | | | 28,347 | | | 78,124 | | | 87,315 | |
General and administrative | 11,768 | | | 10,533 | | | 31,751 | | | 31,784 | |
Restructuring | — | | | — | | | 2,437 | | | — | |
Total operating expenses | 43,606 | | | 38,880 | | | 112,312 | | | 119,099 | |
Loss from operations | (28,244) | | | (27,808) | | | (81,905) | | | (101,604) | |
Other income (expense), net: | | | | | | | |
Interest expense and amortization of long-term debt − related party | — | | | (167) | | | — | | | (1,373) | |
Loss on early extinguishment of debt | — | | | (621) | | | — | | | (621) | |
Interest and other income, net | 3,578 | | | 2,562 | | | 11,162 | | | 6,862 | |
Total other income, net | 3,578 | | | 1,774 | | | 11,162 | | | 4,868 | |
Loss before income taxes | (24,666) | | | (26,034) | | | (70,743) | | | (96,736) | |
Income tax expense | — | | | (1,003) | | | — | | | (1,003) | |
Net loss | $ | (24,666) | | | $ | (27,037) | | | $ | (70,743) | | | $ | (97,739) | |
Net loss per share − basic and diluted | $ | (0.35) | | | $ | (0.55) | | | (1.03) | | | (1.99) | |
Weighted-average shares outstanding − basic and diluted | 69,627,190 | | | 49,212,126 | | | 68,958,938 | | | 49,103,351 | |
| | | | | | | |
Other comprehensive loss: | | | | | | | |
Unrealized gain on marketable securities | 895 | | | 870 | | | 582 | | | 3,233 | |
Comprehensive loss | $ | (23,771) | | | $ | (26,167) | | | $ | (70,161) | | | $ | (94,506) | |
See accompanying notes to unaudited condensed consolidated financial statements.
C4 Therapeutics, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | Additional Paid-In Capital | | Accumulated Other Comprehensive Income (Loss) | | Accumulated Deficit | | Total Stockholders' Equity |
| Shares | | Amount | | | | |
Balance as of December 31, 2023 | 60,467,188 | | | $ | 6 | | | $ | 774,618 | | | (127) | | | $ | (528,383) | | | $ | 246,114 | |
Issuance of common stock pursuant to the Betta Pharma Stock Purchase Agreement | 5,567,928 | | | 1 | | | 19,999 | | | — | | | — | | | 20,000 | |
Issuance of common stock pursuant to the at-the-market equity program, net | 2,500,601 | | | — | | | 14,089 | | | — | | | — | | | 14,089 | |
Issuance of common stock upon exercise of stock options | 80,936 | | | — | | | 519 | | | — | | | — | | | 519 | |
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding | 121,516 | | | — | | | (109) | | | — | | | — | | | (109) | |
Issuance of common stock under 2020 ESPP | 34,902 | | | — | | | 84 | | | — | | | — | | | 84 | |
Stock-based compensation | — | | | — | | | 6,215 | | | — | | | — | | | 6,215 | |
Change in unrealized loss, net on marketable securities | — | | | — | | | — | | | (253) | | | — | | | (253) | |
Net loss | — | | | — | | | — | | | — | | | (28,361) | | | (28,361) | |
Other | 5,520 | | | — | | | (16) | | | — | | | — | | | (16) | |
Balance as of March 31, 2024 | 68,778,591 | | | $ | 7 | | | $ | 815,399 | | | $ | (380) | | | $ | (556,744) | | | $ | 258,282 | |
Exercise of stock options and release of stock units | 32,607 | | | — | | | 135 | | | — | | | — | | | 135 | |
Stock-based compensation | — | | | — | | | 6,381 | | | — | | | — | | | 6,381 | |
Change in unrealized loss, net on marketable securities | — | | | — | | | — | | | (60) | | | — | | | (60) | |
Net loss | — | | | — | | | — | | | — | | | (17,716) | | | (17,716) | |
Other | 4,444 | | | — | | | 36 | | | — | | | — | | | 36 | |
Balance as of June 30, 2024 | 68,815,642 | | | $ | 7 | | | $ | 821,951 | | | $ | (440) | | | $ | (574,460) | | | $ | 247,058 | |
Issuance of common stock pursuant to the at-the-market equity program, net | 1,631,521 | | | — | | | 10,280 | | | — | | | — | | | 10,280 | |
Exercise of stock options and release of stock units | 1,714 | | | — | | | 13 | | | — | | | — | | | 13 | |
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding | 31,363 | | | — | | | (85) | | | — | | | — | | | (85) | |
Issuance of common stock under 2020 ESPP | 75,993 | | | — | | | 298 | | | — | | | — | | | 298 | |
Stock-based compensation | — | | | — | | | 8,831 | | | — | | | — | | | 8,831 | |
Change in unrealized loss, net on marketable securities | — | | | — | | | — | | | 895 | | | — | | | 895 | |
Net loss | — | | | — | | | — | | | — | | | (24,666) | | | (24,666) | |
Other | 6,668 | | | — | | | 32 | | | — | | | — | | | 32 | |
Balance as of September 30, 2024 | 70,562,901 | | | $ | 7 | | | $ | 841,320 | | | $ | 455 | | | $ | (599,126) | | | $ | 242,656 | |
See accompanying notes to unaudited condensed consolidated financial statements.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | Additional Paid-In Capital | | Accumulated Other Comprehensive Income (Loss) | | Accumulated Deficit | | Total Stockholders' Equity |
| Shares | | Amount | | | | |
Balance as of December 31, 2022 | 48,966,216 | | | $ | 5 | | | $ | 689,256 | | | $ | (4,137) | | | $ | (395,890) | | | $ | 289,234 | |
Issuance of common stock upon exercise of stock options | 11,759 | | | — | | | 56 | | | — | | | — | | | 56 | |
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding | 48,730 | | | — | | | (94) | | | — | | | — | | | (94) | |
Issuance of common stock under 2020 ESPP | 20,748 | | | — | | | 104 | | | — | | | — | | | 104 | |
Stock-based compensation | — | | | — | | | 6,251 | | | — | | | — | | | 6,251 | |
Change in unrealized loss, net on marketable securities | — | | | — | | | — | | | 1,667 | | | — | | | 1,667 | |
Net loss | — | | | — | | | — | | | — | | | (34,780) | | | (34,780) | |
Other | 5,056 | | | — | | | 32 | | | — | | | — | | | 32 | |
Balance as of March 31, 2023 | 49,052,509 | | | $ | 5 | | | $ | 695,605 | | | $ | (2,470) | | | $ | (430,670) | | | $ | 262,470 | |
Exercise of stock options and release of stock units | 1,337 | | | — | | | 2 | | | — | | | — | | | 2 | |
Stock-based compensation | — | | | — | | | 6,425 | | | — | | | — | | | 6,425 | |
Change in unrealized loss, net on marketable securities | — | | | — | | | — | | | 696 | | | — | | | 696 | |
Net loss | — | | | — | | | — | | | — | | | (35,922) | | | (35,922) | |
Other | 11,252 | | | — | | | 36 | | | — | | | — | | | 36 | |
Balance as of June 30, 2023 | 49,065,098 | | | $ | 5 | | | $ | 702,068 | | | $ | (1,774) | | | $ | (466,592) | | | $ | 233,707 | |
Exercise of stock options and release of stock units | — | | | — | | | — | | | — | | | — | | | — | |
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding | 69,015 | | | — | | | (16) | | | — | | | — | | | (16) | |
Issuance of common stock under 2020 ESPP | 113,036 | | | — | | | 264 | | | — | | | — | | | 264 | |
Stock-based compensation | — | | | — | | | 8,200 | | | — | | | — | | | 8,200 | |
Change in unrealized loss, net on marketable securities | — | | | — | | | — | | | 870 | | | — | | | 870 | |
Net loss | — | | | — | | | — | | | — | | | (27,037) | | | (27,037) | |
Other | 12,721 | | | — | | | 36 | | | — | | | — | | | 36 | |
Balance as of September 30, 2023 | 49,259,870 | | | $ | 5 | | | $ | 710,552 | | | $ | (904) | | | $ | (493,629) | | | $ | 216,024 | |
See accompanying notes to unaudited condensed consolidated financial statements.
C4 Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited) | | | | | | | | | | | |
| Nine Months Ended September 30, |
| 2024 | | 2023 |
Cash flows used in operating activities: | | | |
Net loss | $ | (70,743) | | | $ | (97,739) | |
Adjustments to reconcile net loss to cash used in operating activities: | | | |
Stock-based compensation expense | 21,427 | | | 20,876 | |
Depreciation and amortization expense | 1,338 | | | 1,450 | |
Reduction in carrying amount of right-of-use asset | 4,790 | | | 4,596 | |
Net accretion of discounts on marketable securities | (4,315) | | | (2,817) | |
Amortization of debt discount − related party | — | | | 405 | |
Loss on early extinguishment of debt | — | | | 621 | |
Other | 53 | | | 120 | |
Changes in operating assets and liabilities: | | | |
Accounts receivable | 1,458 | | | 973 | |
Prepaid expenses and other current and long-term assets | (4,300) | | | 1,404 | |
Accounts payable | 57 | | | 104 | |
Accrued expenses and other current liabilities | (5,242) | | | (3,866) | |
Operating lease liability | (3,881) | | | (3,489) | |
Deferred revenue | 12,133 | | | (5,467) | |
Net cash used in operating activities | (47,225) | | | (82,829) | |
Cash flows (used in) provided by investing activities: | | | |
Proceeds from maturities of marketable securities | 178,781 | | | 219,975 | |
Purchases of marketable securities | (243,537) | | | (92,020) | |
Purchases of property and equipment, net | (184) | | | (1,551) | |
Net cash (used in) provided by investing activities | (64,940) | | | 126,404 | |
Cash flows provided by (used in) financing activities: | | | |
Proceeds from issuance of common stock pursuant to the at-the-market equity program, net | 24,370 | | | — | |
Proceeds from issuance of common stock pursuant to the Betta Pharma Stock Purchase Agreement | 20,000 | | | — | |
Proceeds from exercise of stock options | 667 | | | 58 | |
Payments for repurchase of common stock for tax withholding | (194) | | | (110) | |
Payment of long-term debt − related party | — | | | (12,500) | |
Other | 381 | | | 369 | |
Net cash provided by (used in) financing activities | 45,224 | | | (12,183) | |
| | | |
Net change in cash, cash equivalents and restricted cash | (66,941) | | | 31,392 | |
Cash, cash equivalents and restricted cash at beginning of period | 130,033 | | | 33,033 | |
Cash, cash equivalents and restricted cash at end of period | $ | 63,092 | | | $ | 64,425 | |
| | | |
Reconciliation of cash, cash equivalents and restricted cash: | | | |
Cash, cash equivalents and restricted cash at end of period | $ | 63,092 | | | $ | 64,425 | |
Less: restricted cash | (3,443) | | | (3,454) | |
Cash and cash equivalents at end of the period | $ | 59,649 | | | $ | 60,971 | |
C4 Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows - Continued
(in thousands)
(Unaudited)
| | | | | | | | | | | |
| Nine Months Ended September 30, |
| 2024 | | 2023 |
Supplemental disclosures of cash flow information: | | | |
Cash paid for leases | $ | 6,614 | | | $ | 6,421 | |
Cash paid for income taxes | $ | — | | | $ | 1,003 | |
Cash paid for interest − related party | $ | — | | | $ | 990 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
See accompanying notes to unaudited condensed consolidated financial statements.
C4 THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Nature of the business and basis of presentation
C4 Therapeutics, Inc., or, together with its subsidiary, the Company, is a clinical-stage biopharmaceutical company dedicated to the advancement of targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. The Company leverages its proprietary technology platform, TORPEDO (Target ORiented ProtEin Degrader Optimizer), to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing protein, offering the potential to overcome drug resistance, drug undruggable targets, and improve patient outcomes. The Company uses its TORPEDO platform to advance multiple targeted oncology programs to the clinic while expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. The Company was incorporated in Delaware on October 7, 2015 and has its principal office in Watertown, Massachusetts.
Liquidity and capital resources
Since its inception, the Company’s primary activities have been focused on research and development activities, building the Company’s intellectual property, recruiting and retaining personnel, and raising capital to support these activities. To date, the Company has funded its operations primarily with proceeds received from the sales of redeemable convertible preferred stock, public offerings of the Company’s common stock, private placement of the Company's common stock, through its collaboration agreements, and debt financing.
The Company has incurred recurring losses since its inception, including net losses of $70.7 million and $97.7 million for the nine months ended September 30, 2024 and 2023, respectively. In addition, as of September 30, 2024, the Company had an accumulated deficit of $599.1 million. To date, the Company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization. The Company expects to continue to generate operating losses for the foreseeable future.
The Company expects that its cash, cash equivalents, and marketable securities of $284.4 million as of September 30, 2024 will be sufficient to fund its operations for at least the next twelve months from the date of issuance of these consolidated financial statements. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.
Risks and uncertainties
The Company is subject to risks common to other life science companies in the early development stage including, but not limited to, uncertainty of ability to raise additional financing, product development and commercialization, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, lack of marketing and sales history, product liability, protection of proprietary technology and intellectual property, and compliance with regulations from the Food and Drug Administration, or the FDA, and other government agencies. If the Company does not successfully advance its programs into and through human clinical trials and commercialize any of its product candidates either directly or through collaborations with other companies, the Company may be unable to produce product revenue or achieve profitability. There can be no assurance that the Company’s research and development efforts will be successful, adequate protection for the Company’s intellectual property will be obtained, any products developed will obtain necessary government regulatory approval, or any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.
Note 2. Summary of significant accounting policies
Basis of presentation and consolidation
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, regarding interim financial reporting, and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements include the accounts of C4 Therapeutics, Inc. and its subsidiary, C4T Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation.
Unaudited interim financial information
The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and the related interim disclosures are unaudited. These unaudited condensed consolidated financial statements include all adjustments necessary, consisting of only normal recurring adjustments, to fairly state the financial position and the results of the Company’s operations and cash flows for interim periods in accordance with U.S. GAAP. Interim period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for year ended December 31, 2023, and notes thereto, which are included in the Company’s 2023 Annual Report on Form 10-K that was filed with the SEC on February 22, 2024, or the 2023 Annual Report.
Use of estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the condensed consolidated financial statements if these results differ from historical experience or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, amounts and timing of revenues recognized under the Company’s research and development collaboration arrangements, prepaid and accrued research and development expense, incremental borrowing rate used in the measurement of lease liabilities, and estimated volatility used in fair valuation of stock options. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.
Significant accounting policies
The Company’s significant accounting policies are disclosed in the audited condensed consolidated financial statements for the year ended December 31, 2023, which are included in the Company’s 2023 Annual Report on Form 10-K that was filed with the SEC on February 22, 2024. Since the date of those condensed consolidated financial statements, there have been no material changes to the Company’s significant accounting policies.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Report Segment Disclosures (“ASU 2023-07”). ASU 2023-07 requires enhanced disclosures about significant segment expenses, enhanced interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. ASU 2023-07 is effective for the Company’s annual reporting period beginning after December 15, 2023, and subsequent interim periods, with early adoption permitted. ASU 2023-07 requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the effect that adoption of ASU 2023-07 will have on its consolidated financial statements.
Note 3. Fair value measurements
The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2024 (in
thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Fair Value | | Level 1 | | Level 2 | | Level 3 |
Cash equivalents: | | | | | | | |
Money market funds | $ | 46,987 | | | $ | 46,987 | | | $ | — | | | $ | — | |
Corporate debt securities | 6,225 | | | — | | | 6,225 | | | — | |
U.S. Treasury securities | 6,221 | | | — | | | 6,221 | | | — | |
Marketable securities: | | | | | | | |
Corporate debt securities | 188,972 | | | — | | | 188,972 | | | — | |
U.S. Treasury securities | 23,261 | | | — | | | 23,261 | | | — | |
U.S. government debt securities | 12,518 | | | — | | | 12,518 | | | — | |
Total cash equivalents and marketable securities | $ | 284,184 | | | $ | 46,987 | | | $ | 237,197 | | | $ | — | |
There have been no transfers between fair value levels during the nine months ended September 30, 2024.
The following table sets forth the fair value of the Company’s financial assets by level within the fair value hierarchy at December 31, 2023 (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Fair Value | | Level 1 | | Level 2 | | Level 3 |
Cash equivalents: | | | | | | | |
Money market funds | $ | 103,564 | | | $ | 103,564 | | | $ | — | | | $ | — | |
U.S. Treasury securities | 14,972 | | | — | | | 14,972 | | | — | |
Corporate debt securities | 7,588 | | | — | | | 7,588 | | | — | |
Marketable securities: | | | | | | | |
Corporate debt securities | 128,705 | | | — | | | 128,705 | | | — | |
U.S. government debt securities | 20,428 | | | — | | | 20,428 | | | — | |
U.S. Treasury securities | 5,966 | | | — | | | 5,966 | | | — | |
Total cash equivalents and marketable securities | $ | 281,223 | | | $ | 103,564 | | | $ | 177,659 | | | $ | — | |
The Company classifies its money market funds, which are valued based on quoted market prices in active markets, with no valuation adjustment, as Level 1 assets within the fair value hierarchy.
Marketable securities consist of U.S. Treasury securities, U.S. government debt securities, and corporate debt securities, all of which are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies on a recurring basis.
Note 4. Marketable securities
Marketable securities as of September 30, 2024 consisted of the following (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Amortized Cost | | Gross Unrealized Gains | | Gross Unrealized Losses | | Fair Value |
Marketable securities, current: | | | | | | | |
Corporate debt securities | $ | 161,256 | | | $ | 342 | | | $ | (33) | | | $ | 161,565 | |
U.S. Treasury securities | 23,233 | | | 28 | | | — | | | 23,261 | |
U.S. government debt securities | 11,160 | | | 9 | | | (2) | | | 11,167 | |
Marketable securities, non-current: | | | | | | | |
Corporate debt securities | 27,297 | | | 120 | | | (10) | | | 27,407 | |
U.S. government debt securities | 1,350 | | | 1 | | | — | | | 1,351 | |
| | | | | | | |
Total marketable securities, current and non-current | $ | 224,296 | | | $ | 500 | | | $ | (45) | | | $ | 224,751 | |
Marketable securities as of December 31, 2023 consisted of the following (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Amortized Cost | | Gross Unrealized Gains | | Gross Unrealized Losses | | Fair Value |
Marketable securities, current: | | | | | | | |
Corporate debt securities | $ | 100,903 | | | $ | 16 | | | $ | (221) | | | $ | 100,698 | |
U.S. government debt securities | 20,457 | | | 14 | | | (43) | | | 20,428 | |
U.S. Treasury securities | 5,965 | | | 1 | | | — | | | 5,966 | |
Marketable securities, non-current: | | | | | | | |
Corporate debt securities | 27,901 | | | 120 | | | (14) | | | 28,007 | |
| | | | | | | |
| | | | | | | |
Total marketable securities, current and non-current | $ | 155,226 | | | $ | 151 | | | $ | (278) | | | $ | 155,099 | |
Marketable securities classified as current have maturities of less than one year and are classified as available-for-sale. Marketable securities classified as non-current are those that: (i) have a maturity of greater than one year, and (ii) are not intended to be liquidated within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale. No available-for-sale debt securities held as of September 30, 2024 or December 31, 2023 had remaining maturities greater than five years.
Based on factors such as historical experience, market data, issuer-specific factors, and current economic conditions, the Company did not record an allowance for credit losses at September 30, 2024 and December 31, 2023, related to these securities.
Note 5. Property and equipment
Property and equipment consisted of the following (in thousands):
| | | | | | | | | | | |
| September 30, 2024 | | December 31, 2023 |
Property and equipment: | | | |
Laboratory equipment | $ | 8,213 | | | $ | 8,042 | |
Leasehold improvements | 4,712 | | | 4,712 | |
Furniture and fixtures | 1,435 | | | 1,422 | |
Office equipment | 621 | | | 621 | |
| | | |
Computer equipment | 98 | | | 98 | |
Total property and equipment | 15,079 | | | 14,895 | |
Less: accumulated depreciation | (8,873) | | | (7,763) | |
Total property and equipment, net | $ | 6,206 | | | $ | 7,132 | |
Depreciation expense related to property and equipment is as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Depreciation expense | $ | 365 | | | $ | 447 | | | $ | 1,109 | | | $ | 1,450 | |
Note 6. Leases
The Company leases office and laboratory space under a non-cancelable operating lease. In addition, the Company subleases a portion of its office and laboratory space. There have been no material changes to the Company’s lease or sublease during the nine months ended September 30, 2024. For additional information, please read Note 6, Leases, to the audited condensed consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Note 7. Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
| | | | | | | | | | | |
| September 30, 2024 | | December 31, 2023 |
Accrued expenses and other current liabilities: | | | |
Accrued research and development | $ | 8,325 | | | $ | 11,243 | |
Accrued compensation and benefits | 5,247 | | | 7,344 | |
Other | 1,816 | | | 2,043 | |
Total accrued expenses and other current liabilities | $ | 15,388 | | | $ | 20,630 | |
Note 8. Collaboration and license agreements
MKDG Collaboration and License Agreement
On March 1, 2024, the Company entered into a license and collaboration agreement with MKDG, or the MKDG Agreement, to discover two targeted protein degraders against critical oncogenic proteins.
Under the terms of the MKDG Agreement, the Company grants MKDG a worldwide, exclusive license under certain of the Company's intellectual property rights to develop, manufacture, and commercialize two targeted protein degraders against critical oncogenic proteins. MKDG is responsible for all development, regulatory approval, manufacturing and commercialization costs. Under the terms of the MKDG Agreement, MKDG agreed to make an upfront cash payment of $16.0 million and to fund the Company's discovery research efforts. The Company is eligible to receive approximately $740 million in the aggregate in discovery, regulatory, and commercial milestone payments across the collaboration, plus tiered royalties on net sales. Royalties payable from MKDG to the Company range from mid-single digit to low-double digit percent, subject to reductions under certain circumstances as described in the MKDG Agreement.
The collaboration is managed by a joint research committee, or MKDG JRC, and a joint steering committee, or MKDG JSC, each of which is comprised of representatives of MKDG and the Company. Under the MKDG Agreement, MKDG has final decision-making authority over the MKDG JSC, which has the authority to decide matters that cannot be resolved by the MKDG JRC. MKDG may terminate the MKDG Agreement on a project-by-project basis or in its entirety upon 60 days’ prior written notice. Each party also has various termination rights under certain circumstances, including but not limited to patent challenges, insolvency, or a material breach by the other party, subject to certain conditions.
MKDG Agreement Accounting
The Company identified two performance obligations at the outset of the MKDG Agreement, represented by the two potential research and development targets. While the Company is obligated under the MKDG Agreement to provide the exclusive license and perform certain research activities, the Company determined that the license, the research activities, and participation on the MKDG JRC and MKDG JSC are considered promised services. Participation on the MKDG JRC and MKDG JSC to oversee the research activities contemplated under the MKDG Agreement were determined to be quantitatively and qualitatively immaterial and, therefore, were excluded from the performance obligations. The total transaction price of the MKDG Agreement is allocated to the performance obligations based on their relative standalone selling price. The Company recognizes the transaction price allocated to the performance obligations as the research and development services are provided, using an input method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation. Incremental fees for research and development services are paid at agreed upon FTE rates and recognized as revenue in the period incurred.
As of September 30, 2024, the total transaction price of $16.0 million is allocated to the two performance obligations and $14.4 million remains unsatisfied.
Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company’s condensed consolidated balance sheet.
Merck License and Collaboration Agreement
On December 11, 2023, the Company entered into an exclusive license and collaboration agreement with Merck, or the Merck Agreement, to develop degrader-antibody conjugates, or DACs, an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.
Under the terms of the Merck Agreement, the Company received a $10.0 million upfront payment. The Company and Merck will collaborate to develop DACs directed to an initial undisclosed oncology target that is exclusive to the collaboration. For DACs directed to this initial target, the Company is eligible to receive milestone payments totaling approximately $600 million, as well as tiered royalties on future sales. The Merck Agreement also provides Merck with the option to extend the collaboration to include three additional targets that would be exclusive to the collaboration, which could yield option exercise payments as well as potential milestones and royalties. If Merck exercises all of its options to extend the collaboration, the Company would be eligible to receive up to approximately $2.5 billion in potential payments across the entire collaboration.
The collaboration is managed by a joint research committee, or Merck JRC, which is comprised of representatives from both Merck and the Company. Merck may terminate the Merck Agreement, in its entirety or as to a given target, for convenience upon at least 60 days’ prior notice. Each party also has various termination rights under certain circumstances, including but not limited to regulatory safety stoppages, patent challenges, insolvency, or a material breach by the other party, subject to certain conditions.
Merck Agreement Accounting
The Company identified one performance obligation at the outset of the Merck Agreement, which consists of: (1) the exclusive license and (2) the research activities for the initial undisclosed oncology target and the joint research plan. The Company determined that the license and research activities were not distinct from one another, as the license has limited value without the performance of the research activities by the Company. Participation on the Merck JRC to oversee the research activities and the technology transfer associated with the Merck Agreement were determined to be quantitatively and qualitatively immaterial and therefore are excluded from performance obligations. The Company recognizes the transaction price allocated to this performance obligation as the research and development services are provided, using an input method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation. The transfer of control occurs over this period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation.
As of September 30, 2024, the total transaction price of $10.0 million is allocated to the research and development services performance obligation and $6.6 million of the allocated transaction price remains unsatisfied.
Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company’s consolidated balance sheet.
Betta Pharma License and Collaboration Agreement - Related Party
On May 29, 2023, the Company entered into a license and collaboration agreement, or the Betta Pharma License Agreement, with Betta Pharma to collaborate on the development, manufacturing, and commercialization of CFT8919 in Greater China, comprised of mainland China, Hong Kong SAR, Macau SAR and Taiwan, with the Company retaining rights to CFT8919 in the rest of the world other than Greater China, or the C4T Territory.
Under the terms of the Betta Pharma License Agreement, the Company grants Betta Pharma an exclusive license under certain of the Company's intellectual property rights to develop, manufacture and commercialize CFT8919 for all uses in humans in Greater China. Betta Pharma is responsible for all development, regulatory approval, manufacturing and commercialization costs in Greater China except where Betta Pharma acts as the Company's agent in Greater China in connection with a global trial sponsored by the Company. As part of the collaboration, Betta Pharma made an upfront cash payment of $10.0 million to the Company and has agreed to make up to $357.0 million in aggregate milestone payments, plus tiered royalties on net sales of CFT8919 in Greater China. These payments are subject to a withholding tax by the State Taxing Authority of the People's Republic of China. Royalties payable from Betta Pharma to the Company range from low to mid double-digit percent, subject to certain reductions under certain circumstances as described in the Betta Pharma License Agreement. In addition, as part of the collaboration, the Company has agreed to make milestone payments to Betta Pharma of up to $40.0 million following the Company's receipt of approval of a New Drug Application for CFT8919 from the FDA, with the milestone amount based on the percentage of patients in contemplated clinical trials that were enrolled by Betta Pharma and the line of therapy of the approval. In addition, the Company has agreed to pay Betta Pharma tiered royalties on net sales of CFT8919 in the C4T Territory in the low single digit percent range, subject to reductions under certain circumstances as described in the Betta Pharma License Agreement.
In connection with the execution of the Betta Pharma License Agreement, the Company, Betta Pharma, and an affiliate of Betta Pharma, (Betta Investment (Hong Kong) Limited, or Betta Investment), entered into a stock purchase agreement dated May 29, 2023, or the Betta Stock Purchase Agreement, and together with the Betta Pharma License Agreement, the Betta Agreements, pursuant to which Betta Investment agreed to purchase 5,567,928 shares of the Company's common stock, or the Shares, for an aggregate purchase price of approximately $25.0 million, or $4.49 per share, which represented
a 25% premium over the 60-trading-day volume weighted average closing price as of two trading days prior to the effective date of the Betta Stock Purchase Agreement. The Betta Stock Purchase Agreement has certain restrictions customary to agreements of this nature. The closing under the Betta Stock Purchase Agreement occurred on January 4, 2024. Due to Betta Investment's purchase of shares of the Company's common stock in January 2024 under the Betta Stock Purchase Agreement, its subsequent filing of a Schedule 13G on January 12, 2024, and its relationship with Betta Pharma as an affiliate, Betta Pharma is considered a related party to the Company.
The collaboration is managed by a joint steering committee, which is composed of representatives from both Betta Pharma and the Company. Following the completion of the dose escalation phase of the Phase 1 trial of CFT8919, Betta Pharma may terminate the Betta Pharma License Agreement for convenience upon at least 90 days’ prior written notice. Each party also has various termination rights under certain circumstances, including but not limited to regulatory safety stoppages, patent challenges, insolvency, or a material breach by the other party, subject to certain conditions.
Betta Agreements accounting
The Company expects to recognize revenue under the Betta Agreements from one type of arrangement, the licensing agreement. The Betta Agreements will consist of the following activities: (1) license of intellectual property, (2) clinical supply agreement, (3) manufacturing technology transfer, and (4) commercial manufacturing supply agreement. The clinical supply agreement, or the Betta Pharma Supply Agreement, was signed on August 31, 2024. The Company recognizes the transaction price allocated to the performance obligation as the costs related to manufactured clinical supply are incurred, using an input method, in proportion to costs incurred to date as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation. The clinical manufacturing costs are paid at agreed upon rates and included in the estimated transaction price. The estimated transaction price as of September 30, 2024 is $135.7 million, consisting of the $10.0 million upfront cash consideration, $5.0 million from the closing of the Betta Stock Purchase Agreement, a $2.0 million milestone achieved in December 2023 under the Betta Pharma License Agreement, and the estimated consideration expected to be received from the manufactured clinical supply of $118.7 million. This estimate includes a number of assumptions, including but not limited to the duration and total volume of clinical supply to be provided by the Company pursuant to the Betta Pharma Supply Agreement. In the event there are fluctuations in the Company's assumptions, the estimates of consideration expected to be received pursuant to the Betta Pharma Supply Agreement will also change. Due to scientific and technical uncertainties of the clinical trials, the Company cannot be certain that this amount will be recognized as revenue in future periods.
During the three months ended September 30, 2023, the Company made the related withholding tax payment, related to the upfront payment, of $1.0 million to the Chinese tax authorities (See Note 12).
Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company’s consolidated balance sheet.
Roche Collaboration and License Agreement
In March 2016, the Company entered into a license agreement with Roche, which was amended in June 2016 and again in March 2017. The Company and Roche amended and restated that agreement (as so amended) in December 2018. This amended and restated agreement is referred to as the Roche Agreement. Under the Roche Agreement, the Company and Roche agreed to collaborate in the research, development, manufacture and commercialization of target-binding degrader medicines using the Company’s proprietary TORPEDO platform for the treatment of cancers and other indications. Under the Roche Agreement, the Company may elect to opt into certain co-development rights, in which case the Company will receive an increased royalty rate on future product sales from products directed to that target. In addition, if the Company opts into certain co-detailing rights, it is also entitled to reimbursement of certain commercialization costs. Upon entry into the Roche Agreement, the Company received additional upfront consideration of $40.0 million.
In November 2020, the Company signed a further amendment, the effect of which was to provide that the parties would develop up to five potential targets, with Roche maintaining its option rights to license and commercialize products directed to those targets. The November 2020 amendment also provides a mechanism through which the Company and Roche can mutually agree to terminate the Roche Agreement on a target-by-target basis by the entry into a Mutual Target Termination Agreement. Upon the entry into a Mutual Target Termination Agreement, the Roche Agreement provides that all rights and responsibilities for know-how and other intellectual property in support of products that use inhibition as their mode of action revert to Roche and all rights and responsibilities for know-how and other intellectual property in support of products that use degradation as their mode of action revert to the Company. In support of this allocation of rights, Roche provides the Company, and the Company provides Roche, with a perpetual irrevocable, fully paid up, exclusive (even as to party granting the license), sublicensable (including in multiple tiers) license to the patents and know-how that are allocated to a party under a Mutual Target Termination Agreement. As the research activities with Roche have progressed and
evolved over time, there are now two targets on which the parties continue to collaborate, with Roche maintaining its option rights to license and commercialize products directed to those two targets. In December 2023, the Company signed a second amendment to the Roche Agreement, the effect of which was to update the terms of the agreement as it pertains to the two targets on which the parties continue to collaborate. Under the second amendment to the Roche Agreement, Roche retains its option rights to license and commercialize products directed to those targets but the timing of its option rights are adjusted to begin upon Roche's receipt of the dose range finding data package. There was no material impact to the accounting in 2023 as a result of the second amendment to the Roche Agreement.
Under the Roche Agreement, as amended, the Company receives annual research plan payments of $1.0 million for each active research plan. For the two targets that remain under collaboration among the parties, Roche is required to pay the Company fees of $2.0 million upon the progression of targets to the lead series identification achievement phase. In the event Roche exercises its option rights as to one of these targets, Roche is required to pay the Company an option exercise fee of $8.0 million.
Under the Roche Agreement, as amended, for each target option exercised by Roche, the Company is eligible to receive milestone payments up to $273.0 million upon the achievement of certain development milestones with respect to corresponding products, subject to certain reductions and exclusions based on intellectual property coverage. Roche is also required to pay the Company up to $150.0 million per target in one-time sales-based milestone payments upon the achievement of specified levels of net sales of a product directed to such target. Finally, Roche is required to pay the Company tiered royalties ranging from the mid-single digits to mid-teen percentages on net sales of products sold by Roche pursuant to its exercise of its option rights, subject to certain reductions. For sales of products for which the Company exercises its co-development right, the applicable royalty rates will be increased by a low-single digit percentage.
The collaboration is managed by a joint research committee, or Roche JRC. The Company has control over the Roche JRC prior to Roche’s exercise of its option rights as to a particular target, with Roche assuming control of the Roche JRC thereafter, Roche may terminate the Roche Agreement on a target-by-target or product-by-product basis under several scenarios, upon at least 90 days’ prior written notice. Each party also has various termination rights under certain circumstances, including but not limited to insolvency or a material breach by the other party, subject to certain conditions.
Roche Agreement accounting
At commencement, the Company identified twelve performance obligations within the Roche Agreement, represented by the six potential research and development targets then included in the collaboration and the option rights held by Roche for each of those six targets. A non-exclusive royalty-free license to use the Company’s intellectual property to conduct research and development activities and participation on Roche JRC were identified as promised services. However, the Company determined that the research and development license and research and development services were not distinct from one another, and participation on the Roche JRC was determined to be quantitatively and qualitatively immaterial.
The total transaction price of the Roche Agreement is allocated to the performance obligations based on their relative standalone selling price. The allocated transaction price is recognized as revenue from collaboration agreements in one of two ways:
•Research and development targets: The Company recognizes the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an input method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation related to said research and development target. The transfer of control occurs over this period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation.
•Option rights: The transaction price allocated to the options rights, which are considered material rights, is recognized in the period that Roche elects to exercise or elects to not exercise its option right to license and commercialize the underlying research and development target.
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of September 30, 2024 (in thousands):
| | | | | | | | | | | |
| Transaction Price Allocated | | Transaction Price Unsatisfied |
Performance obligations: | | | |
Research and development targets | $ | 16,688 | | | $ | 13,823 | |
Option rights | 2,376 | | | 2,376 | |
Total | $ | 19,064 | | | $ | 16,199 | |
Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company’s condensed consolidated balance sheet.
Biogen Collaboration Research and License Agreement
In December 2018, the Company entered into a collaboration research and license agreement, or the Biogen Agreement, with Biogen. In February 2020, the Company and Biogen amended the Biogen Agreement to provide further clarity around Biogen’s ownership of target binding moieties (which are portions of molecules), and any related intellectual property that are directed at or bind to collaboration targets. This amendment further provided that Biogen licenses to the Company rights to use these Biogen target binding moieties and any related intellectual property as needed in order to conduct the research and development activities contemplated under the Biogen Agreement. Pursuant to the terms of the Biogen Agreement, the Company and Biogen agreed to collaborate on research activities to develop novel treatments for neurological conditions such as Alzheimer's disease and Parkinson's disease through medicines that rely on target protein degradation, or TPD, as their mode of action, all of which are created using the Company’s degrader technology. Under the terms of the Biogen Agreement, the Company was engaged to develop TPD therapeutics that utilize degrader technology for up to five target proteins over a period of 54 months, ending in June 2023. On a target-by-target basis, after successful completion of a defined target evaluation period, Biogen assumes full rights and responsibility for continued development of each target. As of June 30, 2024, the research term of the Biogen Agreement has been fully satisfied.
In exchange for the non-exclusive research license from Biogen, as well as a $45.0 million nonrefundable upfront payment, the Company has granted a license to develop, commercialize, and manufacture products related to each of the targets (which is contingent on not cancelling the agreement), performs initial research services for drug discovery, has provided a non-exclusive research and commercial license to its intellectual property, and participates on the joint steering committee, or the Biogen JSC. The Company was also obligated to participate in early research activities for other potential targets or sandbox activities, at Biogen’s election up to a maximum amount; any work performed for these services is reimbursed by Biogen, and Biogen reimburses the Company for certain full-time equivalent, or FTE, costs. The Company’s obligations under the sandbox activities were completed as of August 31, 2021. For any target, following the achievement of development candidate criteria and prior to any IND-enabling study, Biogen will bear all costs and expenses of and will have sole discretion and decision-making authority with respect to the performance of further activities with respect to any degrader under development under the Biogen Agreement and all products that incorporate that degrader. Biogen is also required to pay the Company up to $35.0 million per target in development milestones and $26.0 million per target in one-time sales-based payments for the first product to achieve certain levels of net sales. In addition, Biogen is required to pay the Company royalties on a licensed product-by-licensed product basis, on worldwide net product sales. All milestone and sales-based payments are made after the Company has met the defined criteria in the joint research plan for that target, at which time Biogen will have control of the products related to the targets for commercialization; the receipt of these payments is contingent on the further development of products directed to the targets to commercialization by Biogen, without any additional research and development efforts from the Company.
Biogen Agreement accounting
As of September 30, 2024, the total transaction price of the Biogen Agreement of $55.0 million was allocated to the research and development services performance obligation, and the transaction price has been fully allocated and satisfied.
In April 2024, the Company earned an $8.0 million milestone payment from Biogen after the Company accepted delivery of a development candidate in an undisclosed indication. In September 2024, the Company earned an additional $8.0 million milestone payment from Biogen after Biogen accepted delivery of a development candidate in a separate undisclosed indication. The Company's performance obligation under the Biogen Agreement is fully satisfied, and the Company has recognized the full amount as revenue during the three and nine months ended September 30, 2024. Biogen is responsible for all future clinical development and commercialization for this program.
Calico Collaboration and License Agreement
In March 2017, the Company entered into a collaboration and license agreement, or the Calico Agreement, with Calico whereby the Company and Calico agreed to collaborate to develop and commercialize small molecule protein degraders for diseases of aging, including cancer, for a five-year period ending in March 2022. In August 2021, the Company provided an extension option to Calico, which Calico exercised in September 2021, resulting in a $1.0 million extension payment to extend the research term with respect to a certain program for up to a one-year period that ended in March 2023. In addition, Calico reimbursed the Company for a number of FTEs, depending on the stage of the research, at specified market rates. As of March 13, 2023, the research term of the Calico Agreement has expired, and the Company's research activities associated with the agreement are complete.
Under the Calico Agreement, Calico paid an upfront amount of $5.0 million and certain annual payments totaling $5.0 million through June 30, 2020 and paid target initiation fees and reimbursed the Company for a number of FTEs, depending on the stage of the research, at specified market rates. For each target, the Company is eligible to receive up to $132.0 million in potential development and commercial milestone payments, on sales of all products resulting from the collaboration efforts. Calico is also required to pay the Company up to $65.0 million in one-time sales-based payments for the first product to achieve certain levels of net sales. In addition, Calico is required to pay the Company royalties, at percentages in the mid-single digits, on a licensed product-by-licensed product basis, on worldwide net product sales. All milestone and sales-based payments are made after the Company has met the defined criteria in the joint research plan for that target, at which time Calico will have control of the products related to targets for commercialization; the receipt of these payments by the Company is contingent on the further development of the targets to commercialized products by Calico, without any additional research and development efforts required by the Company.
Summary of revenue recognized from collaboration agreements
Revenue from collaboration agreements for the three and nine months ended September 30, 2024 and 2023 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Revenue from collaboration agreements: | | | | | | | |
MKDG Agreement | $ | 2,368 | | | $ | — | | | $ | 4,317 | | | $ | — | |
Merck Agreement | 1,684 | | | — | | | 3,431 | | | — | |
Betta Agreements | 2,896 | | | — | | | 2,896 | | | — | |
Roche Agreement | 414 | | | 8,223 | | | 2,865 | | | 8,736 | |
Biogen Agreement | 8,000 | | | 2,849 | | | 16,898 | | | 7,689 | |
Calico Agreement | — | | | — | | | — | | | 1,070 | |
Total revenue from collaboration agreements | $ | 15,362 | | | $ | 11,072 | | | $ | 30,407 | | | $ | 17,495 | |
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of September 30, 2024 (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Accounts Receivable | | Deferred Revenue, Current | | Deferred Revenue, Net of Current | | Deferred Revenue, Total |
Supplemental information: | | | | | | | |
MKDG Agreement | $ | 1,572 | | | $ | 4,770 | | | $ | 9,652 | | | $ | 14,422 | |
Merck Agreement | — | | | 6,569 | | | — | | | 6,569 | |
Betta Agreements | 769 | | | 4,203 | | | 11,107 | | | 15,310 | |
Roche Agreement | — | | | 5,227 | | | 7,889 | | | 13,116 | |
Biogen Agreement | 8,000 | | | — | | | — | | | — | |
Total | $ | 10,341 | | | $ | 20,769 | | | $ | 28,648 | | | $ | 49,417 | |
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2023 (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Accounts Receivable | | Deferred Revenue, Current | | Deferred Revenue, Net of Current | | Deferred Revenue, Total |
Supplemental information: | | | | | | | |
Merck Agreement | $ | 10,000 | | | $ | 8,000 | | | $ | 2,000 | | | 10,000 | |
Betta Agreement | 1,799 | | | 4,000 | | | 8,000 | | | 12,000 | |
Roche Agreement | — | | | 2,667 | | | 11,814 | | | 14,481 | |
Biogen Agreement | — | | | 804 | | | — | | | 804 | |
Total | $ | 11,799 | | | $ | 15,471 | | | $ | 21,814 | | | $ | 37,285 | |
Supplemental financial information related to the collaboration and license agreements for the three and nine months ended September 30, 2024 and 2023 are (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Revenue recognized that was included in the contract liability at the beginning of the period | $ | 4,994 | | | $ | 2,664 | | | $ | 9,996 | | | $ | 5,895 | |
| | | | | | | |
As of September 30, 2024, the aggregate amount of the transaction price allocated to performance obligations under the MKDG Agreement, Merck Agreement, Betta Agreements, and Roche Agreement that were partially unsatisfied was $170.0 million. The vast majority of the remaining transaction price to be recognized as revenue is based on the estimated manufactured clinical supply costs under the Betta Pharma collaboration. Due to scientific and technical uncertainties of the clinical trials, the Company cannot be certain that this amount will be recognized as revenue in future periods.
Note 9. Stockholders’ equity
At-The-Market Equity Program
In November 2021, the Company filed an automatically effective registration statement on Form S-3, or the Registration Statement, with the SEC that registers the offering, issuance and sale of an unspecified amount of common stock, preferred stock, debt securities, warrants, and/or units of any combination thereof. Simultaneously, the Company entered into an equity distribution agreement with Cowen and Company, LLC, as sales agent, to provide for the issuance and sale by the Company of up to $200.0 million of common stock from time to time in “at-the-market” offerings under the Registration Statement and related prospectus filed with the Registration Statement, or the ATM Program. During the three and nine months ended September 30, 2024, the Company settled 1,631,521 and 4,132,122 shares for net proceeds of $10.3 million and $24.4 million. No amounts were settled under the ATM Program during the three and nine months ended September 30, 2023. As of September 30, 2024, a total of 15,318,264 shares of the Company's common stock at an average purchase price of $5.54 had been sold through the ATM Program, resulting in net proceeds of $82.3 million.
Note 10. Stock-based compensation
Stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 was classified in the Company’s condensed consolidated statement of operations and comprehensive loss as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Stock-based compensation expense: | | | | | | | |
Research and development | $ | 3,341 | | | $ | 3,906 | | | $ | 8,043 | | | $ | 9,133 | |
General and administrative | 5,490 | | | 4,294 | | | 13,384 | | | 11,743 | |
Total stock-based compensation expense | $ | 8,831 | | | $ | 8,200 | | | $ | 21,427 | | | $ | 20,876 | |
Stock options
During the nine months ended September 30, 2024, the Company granted stock options for the purchase of 3,382,967 shares of common stock with a weighted average exercise price of $6.86 per share and a weighted average grant-date fair
value of $5.62 per shares. As of September 30, 2024, the unrecognized compensation cost related to outstanding stock options was $41.9 million, which is expected to be recognized over a weighted-average period of 2.3 years.
On March 7, 2024, the Company approved an option repricing program applicable to outstanding option awards granted to current employees of the Company under the Company’s 2020 Stock Option and Incentive Plan, or the 2020 Plan, with an exercise price per share greater than or equal to $22.00. The repriced awards have new exercise prices of $11.88 per share for awards held by employees generally and $19.00 per share for awards held by members of the Company's senior leadership team. To receive the benefit of this reduced exercise price, holders of repriced option awards must not, prior to March 7, 2025, (i) voluntarily leave employment with the Company or (ii) exercise the repriced options. The repriced options otherwise remain on their existing terms and conditions as set forth in the 2020 Plan and applicable award agreements. During the three and nine months ended September 30, 2024, the Company recorded an incremental non-cash charge of $0.4 million and $0.9 million related to this option repricing. On October 7, 2024, the 2020 Plan was amended to prohibit the plan's administrator from reducing the exercise price of outstanding stock options or stock appreciation rights or effecting repricing through cancellation and re-grant or cancellation in exchange for cash or other awards without prior stockholder approval.
Performance-based restricted stock units
During the nine months ended September 30, 2024, the Company did not grant any performance-based restricted stock units, or PSUs. In addition, 21,000 PSUs vested during the nine months ended September 30, 2024 upon their respective achievement of performance-based vesting criteria. Upon vesting, each PSU automatically converts into one share of the Company’s common stock. The Company withheld 6,634 shares of its common stock through net-share settlement as consideration for employee tax withholding obligations arising upon vesting of the PSUs, which tax amounts were remitted to the applicable revenue authorities in cash. As of September 30, 2024, the unrecognized compensation cost related to outstanding PSUs with performance-based vesting criteria that are considered not probable of achievement was $2.4 million.
Time-based restricted stock units
During the nine months ended September 30, 2024, the Company issued 1,013,350 restricted stock units, or RSUs, that were subject to time-based vesting conditions to its employees. These RSUs are valued on the grant date using the grant date market price of the underlying shares. A total of 161,862 RSUs vested during the nine months ended September 30, 2024 upon their respective vesting schedules. Upon vesting, each RSU automatically converts into one share of the Company’s common stock. The Company indirectly repurchased 23,349 shares of its common stock through net-share settlement as consideration for employee tax withholding obligations arising upon vesting of the RSUs, which tax amounts were remitted to the applicable revenue authorities by the Company in cash on behalf of the RSU holders. As of September 30, 2024, the unrecognized compensation cost related to outstanding RSUs was $8.9 million, which is expected to be recognized over a weighted-average period of 3.1 years.
Note 11. Commitments and contingencies
Legal proceedings
The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.
Note 12. Loss per share
For periods in which the Company reports a net loss attributable to common stockholders, potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. For purposes of the dilutive net loss per share calculation, stock options, and restricted stock units for which the performance or market vesting conditions have been met are considered to be common stock equivalents, while restricted stock units with performance or market vesting conditions that were not met as of September 30, 2024 are not considered to be common stock equivalents. The Company excluded the following potential common shares presented based on
amounts outstanding at period end from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
| | | | | | | | | | | |
| As of September 30, |
| 2024 | | 2023 |
Anti-dilutive common stock equivalents: | | | |
Options to purchase common stock | 11,849,611 | | | 9,868,099 | |
| | | |
Total anti-dilutive common stock equivalents | 11,849,611 | | | 9,868,099 | |
Basic and diluted loss per share is computed by dividing net loss by the weighted-average common shares outstanding for the three and nine months ended September 30, 2024 and 2023 (in thousands, except share and per share data):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Numerator: | | | | | | | |
Net loss | $ | (24,666) | | | $ | (27,037) | | | $ | (70,743) | | | $ | (97,739) | |
Denominator: | | | | | | | |
Weighted-average number of shares used in computed net loss per share − basic and diluted | 69,627,190 | | | 49,212,126 | | | 68,958,938 | | | 49,103,351 | |
Net loss per share − basic and diluted | $ | (0.35) | | | $ | (0.55) | | | $ | (1.03) | | | $ | (1.99) | |
Note 13. Restructuring
In January 2024, the Company implemented a restructuring plan to better align its workforce with the needs of its business and reduce operating costs that included a reduction in the Company's workforce by 30%. The resulting restructuring expense recognized during the nine months ended September 30, 2024 was $2.4 million, which has all been substantially paid as of June 30, 2024.
Note 14. Income taxes
For the three and nine months ended September 30, 2024, the Company recorded no income tax provision or benefit due to losses generated where no benefit was recorded due to the valuation allowance. The Company continues to maintain a full valuation allowance for its U.S. federal and state deferred tax assets as of September 30, 2024 due to uncertainty regarding future taxable income.
The Company’s effective tax rate in the nine months ended September 30, 2023 was impacted by the Chinese withholding tax obligation related to the upfront payment received in connection with the Betta License Agreement, as described in Note 8, Collaboration and license agreement, to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, which resulted in a tax provision of $(1.0) million and an effective tax rate of (1.0)%.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited condensed consolidated financial statements and notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 22, 2024. As discussed in the section titled “Special Note Regarding Forward-Looking Statements,” the following discussion and analysis contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, those identified below and those discussed in the section titled “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2023.
Business overview
We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transforms patients’ lives. By leveraging our proprietary TORPEDO platform, we have the capability to efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. We believe our novel oral product candidates have the potential to overcome drug resistance often seen with inhibitors, target currently “undruggable” targets and improve patient outcomes. To date, we have successfully designed and advanced several protein degraders into the clinic across a range of target classes and, based on data from our clinical trials, our product candidates have demonstrated robust target degradation.
One of our most advanced product candidates, cemsidomide (CFT7455), is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, currently in clinical development for multiple myeloma, or MM, and non-Hodgkin lymphomas, or NHLs. The United States Food and Drug Administration, or FDA, has granted orphan drug designation to cemsidomide (CFT7455) for the treatment of MM. In December 2023, we presented positive clinical data from the dose escalation portion of the cemsidomide (CFT7455) Phase 1/2 trial as a monotherapy and in combination with dexamethasone in MM. We continue to progress the ongoing Phase 1/2 clinical trial of cemsidomide in MM and NHL.
Our other most advanced product candidate, CFT1946, is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant targets to treat melanoma, non-small cell lung cancer, or NSCLC, colorectal cancer, or CRC, and other malignancies that harbor this mutation. In January 2023, we initiated a first-in-human Phase 1/2 clinical trial of CFT1946 for the treatment of BRAF V600X mutant solid tumors including NSCLC, colorectal cancer and melanoma. In September 2024, we presented initial monotherapy CFT1946 data demonstrating proof of mechanism and early evidence of proof of concept in BRAF V600 mutant solid tumors at the European Society for Medical Oncology (ESMO) Congress 2024. We continue to progress the ongoing Phase 1/2 clinical trial of CFT1946.
Additionally, we are developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. In May 2023, we entered into an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China, including Hong Kong SAR, Macau SAR and Taiwan, with Betta Pharmaceuticals, Co., Ltd, or Betta Pharma. Additionally, the FDA cleared the investigational new drug, or IND, application for CFT8919 and Betta Pharma received clinical trial application clearance for CFT8919 from China's National Medical Product Administration. We expect to initiate clinical trial activities outside Greater China following the completion of Betta Pharma's Phase 1 dose escalation trial in Greater China.
Beyond these initial product candidates, we are further diversifying our pipeline by developing new degraders against both clinically validated and currently undruggable targets for our own proprietary programs, as well as for programs we are developing in collaboration with MKDG, Merck, and Roche.
Financial operations overview
Revenues
To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our revenues to date have been generated through research collaboration and license agreements. We recognize revenue over the expected performance period under each agreement. We expect that our revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any royalties under any of our existing collaboration agreements.
For a description of our collaboration agreements with Roche, Biogen, Calico, Betta Pharma, Merck and MKDG, please see Note 8, Collaboration and license agreements, to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Research and development expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include:
•salaries, benefits, and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;
•expenses incurred under agreements with third parties, including contract research organizations and other third parties that conduct research, preclinical, and clinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical and clinical trials;
•cost of outside consultants, including their fees and related travel expenses;
•costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials;
•facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and
•third-party licensing fees.
We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed consolidated financial statements as prepaid or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.
We expect that our research and development expenses will continue to increase substantially in connection with our planned preclinical and clinical development activities.
General and administrative expenses
General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, legal, business development, and administrative functions. General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax, and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.
We expect that our general and administrative expenses will potentially increase in the future to support increased research and development activities. These increases will likely include higher costs related to the hiring of additional personnel; fees to outside consultants, lawyers and accountants; and investor and public relations costs.
Other income (expense), net
Other income (expense), net primarily consists of the following:
•interest expense and amortization of our long-term debt, which is discussed in greater detail in Note 9, Long-term debt – related party, to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q; and
•interest income earned on our cash, cash equivalents, and marketable securities and accretion of discount on marketable securities.
Results of operations
Comparison of the three and nine months ended September 30, 2024 and 2023
Revenue
Revenue from our collaboration and license agreements consisted of the following for the three and nine months ended September 30, 2024 and 2023 (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Revenue from collaboration agreements: | | | | | | | |
MKDG Agreement | $ | 2,368 | | | $ | — | | | $ | 4,317 | | | $ | — | |
Merck Agreement | 1,684 | | | — | | | 3,431 | | | — | |
Betta Pharma Agreement | 2,896 | | | — | | | 2,896 | | | — | |
Roche Agreement | 414 | | | 8,223 | | | 2,865 | | | 8,736 | |
Biogen Agreement | 8,000 | | | 2,849 | | | 16,898 | | | 7,689 | |
Calico Agreement | — | | | — | | | — | | | 1,070 | |
Total revenue from collaboration agreements | $ | 15,362 | | | $ | 11,072 | | | $ | 30,407 | | | $ | 17,495 | |
The $4.3 million increase in revenue in the three months ended September 30, 2024, as compared to the three months ended September 30, 2023 is primarily driven by the $8.0 million milestone earned under the Biogen Agreement for the accepted delivery of a development candidate in an undisclosed indication and a total of $6.9 million of revenue recognized related to the MKDG, Merck and Betta Pharma collaborations that had activities commence in 2024. This was offset by a $7.8 million decrease in revenue related to the Roche collaboration as a result of our September 2023 completion of research activities for a nominated target.
The $12.9 million increase in revenue in the nine months ended in September 30, 2024, as compared to the nine months ended September 30, 2023 is primarily driven by the $10.6 million increase from start of collaboration activities in 2024 for the MKDG, Merck, and Betta Pharma Agreements, and two milestones earned under the Biogen Agreement. This was offset by a $5.9 million decrease under the Roche Agreement as a result of our September 2023 completion of research activities for a nominated target.
Research and development expense
The following table summarizes our research and development expense for the three and nine months ended September 30, 2024 and 2023 (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Research and development expenses: | | | | | | | |
Personnel expenses | $ | 9,147 | | | $ | 12,066 | | | $ | 25,904 | | | $ | 32,977 | |
Preclinical development and discovery expenses | 9,582 | | | 5,303 | | | 20,461 | | | 21,644 | |
Clinical expenses | 7,138 | | | 4,549 | | | 14,506 | | | 12,136 | |
Facilities and supplies | 2,950 | | | 3,222 | | | 9,336 | | | 10,277 | |
Professional fees | 1,761 | | | 2,119 | | | 5,282 | | | 6,729 | |
Intellectual property and other expenses | 1,260 | | | 1,088 | | | 2,635 | | | 3,552 | |
| | | | | | | |
Total research and development expenses | $ | 31,838 | | | $ | 28,347 | | | $ | 78,124 | | | $ | 87,315 | |
The $3.5 million increase in research and development expense in the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 is primarily driven by:
•a $4.3 million increase in preclinical expenses as a result of the progress made on our collaboration programs; and
•a $2.6 million increase in clinical expenses due to continued progress on our cemsidomide and CFT1946 programs.
These amounts were partially offset by a $2.9 million decrease in personnel costs as a result of our restructuring activities in January 2024.
The $9.2 million decrease in research and development expense in the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023 is primarily driven by:
•a $7.1 million decrease in personnel costs as a result of our restructuring activities;
•a $1.4 million decrease in professional fees; and
•a $1.2 million decrease in preclinical expenses as a result of prioritization of our business towards programs that are in clinical stages.
These amounts were partially offset by a $2.4 million increase in clinical expenses as a result of continued progress on our cemsidomide and CFT1946 programs.
General and administrative expense
The following table summarizes our general and administrative expense for the three and nine months ended September 30, 2024 and 2023 (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
General and administrative expenses: | | | | | | | |
Personnel expenses | $ | 8,929 | | | $ | 8,086 | | | $ | 23,912 | | | $ | 23,151 | |
Professional fees | 1,715 | | | 1,493 | | | 4,773 | | | 5,517 | |
Facilities and other expenses | 1,124 | | | 954 | | | 3,066 | | | 3,116 | |
Total general and administrative expenses | $ | 11,768 | | | $ | 10,533 | | | $ | 31,751 | | | $ | 31,784 | |
The $1.2 million increase in general and administrative expense in the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 is primarily driven by a $0.9 million increase in personnel expenses related to our hiring of key personnel.
General and administrative expense in the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023 remained relatively flat as a result of an increase of $0.8 million for personnel expenses offset by a $0.7 million decrease in professional fees and other expenses.
Restructuring expense
The $2.4 million increase of restructuring expense in the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 is driven by the restructuring plan implemented in January 2024 to better align the
Company's workforce with the needs of the business and reduce operating costs, which resulted in a reduction in the Company's workforce of 30%.
Other income (expense), net
The following table summarizes our other income (expense), net for the three and nine months ended September 30, 2024 and 2023 (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Other income (expense), net: | | | | | | | |
Interest and other income, net | $ | 3,578 | | | $ | 2,562 | | | $ | 11,162 | | | $ | 6,862 | |
Loss on extinguishment of long-term debt | — | | | (621) | | | — | | | (621) | |
Interest expense and amortization of long-term debt − related party | — | | | (167) | | | — | | | (1,373) | |
Total other income, net | $ | 3,578 | | | $ | 1,774 | | | $ | 11,162 | | | $ | 4,868 | |
The $1.8 million increase in other income (expense), net in the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 is primarily driven by a $1.0 million increase in interest and other income resulting from higher interest earned on our investments during the three months ended September 30, 2024 and a $0.6 million decrease in loss on extinguishment of long-term debt.
The $6.3 million increase in other income (expense), net in the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023 is primarily driven by a $4.3 million increase in interest and other income resulting from higher interest earned on our investments during the three months ended September 30, 2024 and a $1.4 million decrease in interest expense from long-term debt.
Liquidity and capital resources
Sources of liquidity
Since inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical programs and our product candidates through clinical development. We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of preferred stock, public offerings of our common stock, private placements of our common stock, and through payments from collaboration partners. As of September 30, 2024, we had cash, cash equivalents and marketable securities of approximately $284.4 million.
Cash flows
The following table summarizes our sources and uses of cash for the periods presented (in thousands):
| | | | | | | | | | | |
| Nine Months Ended September 30, |
| 2024 | | 2023 |
Net change in cash, cash equivalents and restricted cash: | | | |
Net cash used in operating activities | $ | (47,225) | | | $ | (82,829) | |
Net cash (used in) provided by investing activities | (64,940) | | | 126,404 | |
Net cash provided by (used in) financing activities | 45,224 | | | (12,183) | |
Total net change in cash, cash equivalents and restricted cash | $ | (66,941) | | | $ | 31,392 | |
Operating activities
Net cash used in operating activities for the nine months ended September 30, 2024 was driven primarily by the following uses of cash:
•net loss of $70.7 million;
•$5.2 million change in accrued expenses and other current liabilities;
•$4.3 million change in prepaid expenses and other current and long-term assets; and
•$3.9 million change in our operating lease liability.
These were offset by:
•$12.1 million change in deferred revenue due to the upfront payment related to the MKDG Agreement and the allocated transaction price that remains unsatisfied related to the Betta Pharma License Agreement, partially offset by the recognition of revenue under our collaboration agreements;
•$1.5 million change in accounts receivable, primarily a result of the Merck upfront payment; and
•non-cash expenses of $23.2 million, which primarily consisted of stock-based compensation expense of $21.4 million.
Investing activities
Net cash used in investing activities for the nine months ended September 30, 2024 was driven primarily by $64.8 million of purchases of marketable securities, net of maturities.
Financing activities
Net cash provided by financing activities for the nine months ended September 30, 2024 was driven primarily by:
•$20.0 million in net proceeds for the execution of the Betta Stock Purchase Agreement; and
•$24.4 million in net proceeds from our at-the-market equity program.
Funding requirements
Since our inception, we have incurred significant operating losses, and we expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we advance the preclinical programs and our product candidates through clinical development. In addition, we expect to continue to incur costs associated with operating as a public company.
Specifically, we anticipate that our expenses will increase substantially in the future, if and as we:
•continue our ongoing first-in-human Phase 1/2 trials and initiate and conduct planned first-in-human Phase 1/2 trials for our other product candidates;
•advance additional product candidates into preclinical and clinical development;
•continue to invest in our proprietary TORPEDO platform;
•advance, expand, maintain, and protect our intellectual property portfolio;
•hire additional clinical, regulatory, quality, and scientific personnel;
•add operational, financial and management information systems, and personnel to support our ongoing research, product development, potential future commercialization efforts, operations as a public company and general and administrative roles;
•seek marketing approvals for any product candidates that successfully complete clinical trials; and
•ultimately establish a sales, marketing, and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval.
Because of the numerous risks and uncertainties associated with development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital and operating costs associated with our current and anticipated preclinical and clinical development. Our future capital requirements will depend on many factors, including:
•the progress, costs, and results of ongoing and planned first-in-human Phase 1/2 trials for our lead product candidates and any future clinical development of those lead product candidates;
•the scope, progress, costs, and results of preclinical and clinical development for our other product candidates and development programs;
•the number and development requirements of other product candidates that we pursue;
•the progress and success of our existing and any future collaborations with third-party partners, including whether or not we receive additional research support or milestone payments from our existing collaboration partners upon the achievement of milestones;
•the costs, timing, and outcome of regulatory review of our product candidates;
•the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
•our willingness and ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, for the development or commercialization of current or additional future product candidates;